EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PPAR-gamma regulates PFAS-mediated proinflammatory cytokines in lung epithelial cells

Sadiya Bi Shaikh, Md Imam Faizan, Khursheed Ul Islam, Virender K Rehan, Irfan Rahman

Frontiers in Pharmacology · 03.02.2026 · 17

DOI: 10.3389/fphar.2026.1779345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.02.2026. Verfasst von Sadiya Bi Shaikh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Per and polyfluoroalkyl substances (PFAS), including the legacy compound perfluorooctanesulfonic acid (PFOS), are persistent organic pollutants with long biological half-lives. Emerging evidence suggests a significant accumulation of PFAS/PFOS in the human lung, potentially contributing to inflammation and altered immune responses. However, the role of peroxisome proliferator-activated receptor gamma (PPARγ) signaling in PFAS/PFOS-induced pulmonary toxicity remains unclear.

Methods

Primary human bronchial epithelial (NHBE) cells were exposed to 15 µM binary PFAS mixture (PFOS + PFOA) or quaternary mixture (PFOS, PFOA, PFHxS, GenX) with or without the PPARγ antagonist (15 µM) and/or the PPARγ agonists rosiglitazone (10 µM) or pioglitazone (10 µM) for 24 h. BALB/c mice were orally administered PFOS (2 mg/kg/day) or vehicle control for 2 weeks.

Results

In NHBE cells, PFAS exposure significantly increased IL-6 and IL-8 secretion. Treatment with rosiglitazone or pioglitazone reversed these cytokine increases, whereas co-treatment with the PPARγ antagonist elevated IL-6 and IL-8 levels compared to PFAS exposure alone in epithelial cells. PFOS exposure in mice caused a reduction in lung PPARγ protein levels, while PPARα expression remained unchanged.

Conclusion

These findings demonstrate that PFAS-induced pro-inflammatory cytokines is mediated, at least in part, through PPARγ signaling, and that pharmacological activation of PPARγ signaling can attenuate PFAS-triggered pro-inflammatory cytokine responses in lung epithelial cells.

Schlagwörter

Stichwörter der Autor:innen

PFASPPARγepithelial cellsinflammationlungs

Autor:innen und Institutionen

  • Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States.
  • Division of Neonatology, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, CA, United States.

Zitieren

APA

Shaikh, S. B., Faizan, M. I., Islam, K. U., Rehan, V. K., & Rahman, I. (2026). PPAR-gamma regulates PFAS-mediated proinflammatory cytokines in lung epithelial cells. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1779345

Vancouver

Shaikh SB, Faizan MI, Islam KU, Rehan VK, Rahman I. PPAR-gamma regulates PFAS-mediated proinflammatory cytokines in lung epithelial cells. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1779345

BibTeX
@article{Shaikh2026,
  author = {Shaikh, Sadiya Bi and Faizan, Md Imam and Islam, Khursheed Ul and Rehan, Virender K and Rahman, Irfan},
  title = {PPAR-gamma regulates PFAS-mediated proinflammatory cytokines in lung epithelial cells},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1779345}
}
Kostenlos starten →